Objectives: Octogenarians with Acute Myeloid Leukemia (AML) exhibit poor median survival of 1-3 months after Standard-Dose Induction Chemotherapy (SICT). De novo AML without Erythroblastic And/Or Megakaryocytic Dysplasia (EMD) involving only Granulocyte-Macrophage Line (GM-AML) is associated with a 74-86% Complete Remission (CR) rate after SICT and improved survival in adult patients aged below 65 years. Our aim was to study if octogenarians with GM-AML will achieve CR and improved survival after SICT.Patients and Methods: Consecutive 12 octogenarians with de novo non-M3 AML with 48-94% (median 80%) bone marrow blasts, classified as AML FAB types: 2×M2, 7×M4, and 3×M5 were offered 3+7 type of SICT. Criteria for EMD were dyserythropoiesis 30% and/or dysmegakaryopoiesis 50% or higher.Results: Six cases, all with leucocytes over 15×10 9 /L, opted for SICT. Three cases with GM-AML achieved CR and survived 16.5-28 months on maintenance therapy while 3 cases with EMD-AML did not reach CR and had survival 0.4-2.7 months. Genetic findings in GM-AML cases showed 46, XY, del (12) (p13) with deleted ETV6 gene, 46, XX with NPM1 mutation and negative for FLT3-ITD and in the third case normal karyotype, which was found in two resistant EMD-AML cases. Survival 0.2-4.0 months was observed in the 6 remaining patients (two with GM-AML, 4 with EMD-AML) on palliative or supportive treatment. Conclusion:Octogenarians with GM-AML even with poor performance status (2×PS 3) may achieve CR and survival benefit after SICT, which is further supported by two other elderly GM-AML cases with over 5 years survival.